Clover Biopharmaceuticals, Ltd. (02197)
| Auditor | From | To | Release Date / Document Links | Reason for Change |
|---|---|---|---|---|
| CL Partners CPA | 19-Jun-25 | |||
| CL Partners CPA | 19-May-25 | |||
| Ernst & Young (Hong Kong) | 25-Oct-21 | |||
| Ernst & Young | 19-Jun-25 | Due to the lack of consensus on the audit fee for the year ending December 31, 2025, the Board proposed that EY will retire as the auditor at the conclusion of the AGM upon the expiration of its current term of office. | ||
| Ernst & Young | 19-May-25 | Lack of consensus on the audit fee for the year ending December 31, 2025. |